Star Therapeutics details early data for blood disorder shot, weighs IPO potential

ORLANDO, Fla. — Star Therapeutics said its once-a-month injection for von Willebrand disease substantially cut bleeding rates in a preliminary study, and is thinking about the next moves to complete a larger trial and eventually get the drug to patients. The trial data released Saturday looked at eight patients, and showed that treatment with Star’s shot decreased bleeds by a median of 81%…